EGFR-TKI have been used as a first-line treatment against lung cancer, but the increasing occurrence of drug resistance and the associated adverse sides precludes it widespread application (Maemondo et al., 2010; van Meerbeeck et al., 2011; Chen Z. et al., 2014). This evidence concerns the gene EGFR and lung cancer.